SCHEMBL14468657

SCHEMBL14468657

CC(C)(C)OC(=O)N1CC[C@@H](NC(=O)OCc2ccccc2)[C@@H]1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
CPB1 P15086 2/20 0.47
CTSL P07711 2/20 0.44
CTSB P07858 1/20 0.44
CTSK P43235 1/20 0.44
AGTR2 P50052 1/20 0.44
TSHR P16473 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ABCB1 P08183 1/20 0.43
HTT P42858 1/20 0.43
PDE4B Q07343 1/20 0.42
KLK7 P49862 1/20 0.42
STS P08842 1/20 0.42
SYK P43405 1/20 0.42
PREP P48147 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5941341 1.00 ALDH1A1 (0.47) ALDH1A1GAACPB1CTSLCTSB
SCHEMBL4040280 1.00 ALDH1A1 (0.47) ALDH1A1GAACPB1CTSLCTSB
SCHEMBL31058400 1.00 ALDH1A1 (0.47) ALDH1A1GAACPB1CTSLCTSB
SCHEMBL18337377 0.93 CPB1 (0.48) ALDH1A1GAACPB1CTSLCTSB
SCHEMBL32672364 0.92 CPB1 (0.53) ALDH1A1GAACPB1CTSLCTSB
SCHEMBL25907340 0.92 CPB1 (0.53) ALDH1A1GAACPB1CTSLCTSB
SCHEMBL6347376 0.90 CPB1 (0.46) ALDH1A1GAACPB1CTSLCTSB
SCHEMBL18335958 0.90 CPB1 (0.46) ALDH1A1GAACPB1CTSLCTSB
SCHEMBL18337016 0.89 CPB1 (0.45) ALDH1A1GAACPB1CTSLTSHR
SCHEMBL18337160 0.89 CPB1 (0.45) ALDH1A1GAACPB1CTSLTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3683222-B1 NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2021-10-06 EP disclosed
EP-3683222-A1 NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2020-07-22 EP disclosed
US-10065972-B2 Bicyclic or tricyclic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2018-09-04 US disclosed
EP-3135674-A1 NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2017-03-01 EP disclosed
US-20160376289-A1 NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2016-12-29 US disclosed
US-8772450-B2 Beta-amino acids WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2014-07-08 US disclosed
US-20130023644-A1 BETA-AMINO ACIDS WISCONSIN ALUMNI RESEARCH FOUNDATION 2013-01-24 US disclosed
US-20070154882-A1 Beta-polypeptides that inhibit cytomegalovirus infection NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-07-05 US disclosed
US-20070123709-A1 Beta-amino acids NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123709-A1 Beta-amino acids BCAT1, MARCKS, YWHAZ ALDH1A1 4837/4885GAA 3215/4885CPB1 225/4885
US-20160376289-A1 NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND CBR3, CBR1, CYCS ALDH1A1 2826/4885GAA 4633/4885CPB1 2213/4885
US-20130023644-A1 BETA-AMINO ACIDS BCAT1, MARCKS, YWHAZ ALDH1A1 4837/4885GAA 3215/4885CPB1 225/4885
US-10065972-B2 Bicyclic or tricyclic heterocyclic compound CBR3, CBR1, CYCS ALDH1A1 3047/4885GAA 4645/4885CPB1 2226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.